Cardiovascular Events Reported in Patients With B-Cell Malignancies Treated With Zanubrutinib

Join Dr Angie Seo (Thalheimer Center of Cardio-Oncology, US) and Dr Joe Carver (University of Pennsylvania, US) in the upcoming IC-OS Journal Club, for an in-depth examination of recent findings on cardiovascular events in patients with B-cell malignancies treated with Zanubrutinib.

This session will provide essential insights into the cardiovascular safety profile of Zanubrutinib, exploring incidence rates, risk factors and potential implications for clinical practice. Experts will guide discussions on the management of cardiovascular risk in this patient population, ensuring attendees leave with a clear understanding of current evidence and practical recommendations.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.

This webinar is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BeiGene, BMS/Pfizer Alliance, Eli Lilly and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.